Peter E. Valk (ed.); Dominique Delbeke (ed.); Dale L. Bailey (ed.); David W. Townsend (ed.); Michael N. Maisey (ed.) Springer (2010) Pehmeäkantinen kirja
Springer Sivumäärä: 475 sivua Asu: Pehmeäkantinen kirja Julkaisuvuosi: 2010, 15.12.2010 (lisätietoa) Kieli: Englanti
The use of positron emission tomography (PET) in clinical practice is key to the s- cessful management of many patients with a wide variety of diseases. Whereas in the 1980s and 1990s nuclear medicine physicians struggled to convince other doctors about the potential clinical value of PET, it is now a challenge to keep up with the requests of our clinical colleagues for the various applications of PET. In fact, in most cases the barriers are now related to reimbursement for a given PET procedure. At the time this foreword was written, many FDG/PET procedures are reimbursable, and the U.S. National PET Registry, which is about to be implemented, will allow FDG/PET imaging data to accumulate on rare tumors, while allowing for Center for Medicare and Medicaid Services (CMS) reimbursement. The challenges are now shifting toward solving some of the limitations of FDG/PET through the use of next generation inst- mentation and newer tracers that hold the promise of improving on what is already a remarkable achievement with FDG/PET. It is my hope that there will in fact be an enormous growth of nuclear medicine driven by new imaging tracers that will fuel a growing number of clinical applications.
